Search research articles
Contact Us
Filters
Showing results (21-30 of 37) with videos related to
Page
of 4
Sort By:
BMJ Open
|
April 30, 2013
Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study
Thomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Nephron
|
October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis
Tobias Bomholt, Thomas Idorn, Filip K Knop, et al.
Diabetes Care
|
January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
Frederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
The New England Journal of Medicine
|
May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Diabetes, Obesity & Metabolism
|
July 4, 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
Ofri Mosenzon, Stephen C Bain, Hiddo J L Heerspink, et al.
Circulation
|
December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M Shaman, Stephen C Bain, George L Bakris, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 15, 2019
Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease
Morten B Jørgensen, Thomas Idorn, Casper Rydahl, et al.
Diabetologia
|
June 4, 2014
Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
Nicolai J Wewer Albrechtsen, Bolette Hartmann, Simon Veedfald, et al.
Endocrine Connections
|
November 30, 2020
No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
David S Mathiesen, Jonatan I Bagger, Katrine B Hansen, et al.
Diabetes Care
|
July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
Peter Rossing, George Bakris, Vlado Perkovic, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 37) with videos related to
Sort By:
Page
of 4
BMJ Open
|
April 30, 2013
Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study
Thomas Idorn, Filip K Knop, Morten Jørgensen, et al.
Nephron
|
October 26, 2020
The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis
Tobias Bomholt, Thomas Idorn, Filip K Knop, et al.
Diabetes Care
|
January 28, 2021
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
Frederik Persson, Stephen C Bain, Ofri Mosenzon, et al.
The New England Journal of Medicine
|
May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Vlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Diabetes, Obesity & Metabolism
|
July 4, 2020
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial
Ofri Mosenzon, Stephen C Bain, Hiddo J L Heerspink, et al.
Circulation
|
December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Ahmed M Shaman, Stephen C Bain, George L Bakris, et al.
The Journal of Clinical Endocrinology and Metabolism
|
October 15, 2019
Effect of the Incretin Hormones on the Endocrine Pancreas in End-Stage Renal Disease
Morten B Jørgensen, Thomas Idorn, Casper Rydahl, et al.
Diabetologia
|
June 4, 2014
Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?
Nicolai J Wewer Albrechtsen, Bolette Hartmann, Simon Veedfald, et al.
Endocrine Connections
|
November 30, 2020
No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
David S Mathiesen, Jonatan I Bagger, Katrine B Hansen, et al.
Diabetes Care
|
July 29, 2025
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
Peter Rossing, George Bakris, Vlado Perkovic, et al.
Page
of 4